Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States-Reference-Cited by-同舟云学术

Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States

Published:2006-02-01 Issue:3 Volume:107 Page:904-906
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Landgren Ola¹,Gridley Gloria¹,Turesson Ingemar¹,Caporaso Neil E.¹,Goldin Lynn R.¹,Baris Dalsu¹,Fears Thomas R.¹,Hoover Robert N.¹,Linet Martha S.¹

Affiliation:

1. From the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD; and Section of Hematology, Department of Medicine, Malmö University Hospital, University of Lund, Malmö, Sweden.

Abstract

Abstract The age-adjusted incidence of multiple myeloma (MM) is 2-fold higher in African Americans than in whites. A few small studies have reported a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS) in African Americans versus whites. Etiologic factors for MGUS and determinants for transformation of MGUS to MM are unknown. We quantified the prevalence of MGUS and subsequent risk of MM among 4 million African American and white male veterans admitted to Veterans Affairs (VA) hospitals. The age-adjusted prevalence ratio of MGUS in African Americans compared with whites was 3.0 (2.7-3.3 95% confidence interval). Among 2046 MGUS cases, the estimated cumulative risk of MM during the first 10 years of follow-up was similar (P = .37) for African Americans (17%) and whites (15%). In the largest study to date, we suggest that the excess risk of MM in African Americans results from an increase in risk of MGUS rather than an increased risk of progression from MGUS to MM.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/107/3/904/1281421/zh800306000904.pdf

Reference8 articles.

1. Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER Cancer Statistics Review, 1975-2000. Bethesda, MD: National Cancer Institute; 2003.

2. Axelsson U, Bachmann R, Hallen J. Frequency of pathological proteins (M-components) in 6,995 sera from an adult population. Acta Med Scand. 1966;179: 235-247.

3. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346: 564-569.

4. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104: 607-618.

5. Chng WJ, Van Wier SA, Ahmann GJ, et al. A validated FISH trisomy index demonstrates the hyperdiploid and non-hyperdiploid dichotomy in MGUS. Blood. 2005;106: 2156-2161.

Cited by 271 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors Associated With Survival Among Patients With Multiple Myeloma in Northeastern Tanzania;JCO Global Oncology;2024-08

2. Monoclonal Gammopathy of Undetermined Significance and Associated Cardiovascular Outcomes in a Hospital Setting—A Fresh Perspective;Current Oncology;2024-08-01

3. Prevalence of monoclonal gammopathy of undetermined significance in Eswatini: a population-based study in Africa;JNCI Cancer Spectrum;2024-07-01

4. Multiple myeloma incidence and mortality trends in the United States, 1999–2020;Scientific Reports;2024-06-24

5. Anthropometric traits and risk of multiple myeloma: differences by race, sex and diagnostic clinical features;British Journal of Cancer;2024-06-07